Atea Pharmaceuticals Inc
NASDAQ:AVIR
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Atea Pharmaceuticals Inc
NASDAQ:AVIR
|
US |
|
R
|
Robit Oyj
OMXH:ROBIT
|
FI |
|
OFX Group Ltd
ASX:OFX
|
AU |
|
Select Harvests Ltd
ASX:SHV
|
AU |
|
YS Biopharma Co Ltd
NASDAQ:LSB
|
CN |
|
Brainsway Ltd
NASDAQ:BWAY
|
IL |
Atea Pharmaceuticals Inc
Atea Pharmaceuticals, Inc. is a clinical stage company, which focuses on discovering, developing, and commercializing antiviral therapeutics. The company is headquartered in Boston, Massachusetts and currently employs 59 full-time employees. The company went IPO on 2020-10-30. The firm is focused on discovering, developing, and commercializing antiviral therapeutics to enhance the lives of patients suffering from life-threatening viral infections. The firm is engaged in the development of product candidates to treat COVID-19, hepatitis C virus (HCV), dengue and respiratory syncytial virus (RSV). The firm is developing bemnifosbuvir (AT-527), which is an investigational, novel, orally administered guanosine nucleotide analog polymerase inhibitor for the treatment of COVID-19. The company is developing bemnifosbuvir and ruzasvir, an investigational nonstructural protein 5A (NS5A) inhibitor for the treatment of chronic HCV infection. The firm is also developing AT-752, an oral, purine nucleotide prodrug for the treatment of dengue. AT-527 is designed to inhibit viral replication by interfering with viral RNA polymerase.
Atea Pharmaceuticals, Inc. is a clinical stage company, which focuses on discovering, developing, and commercializing antiviral therapeutics. The company is headquartered in Boston, Massachusetts and currently employs 59 full-time employees. The company went IPO on 2020-10-30. The firm is focused on discovering, developing, and commercializing antiviral therapeutics to enhance the lives of patients suffering from life-threatening viral infections. The firm is engaged in the development of product candidates to treat COVID-19, hepatitis C virus (HCV), dengue and respiratory syncytial virus (RSV). The firm is developing bemnifosbuvir (AT-527), which is an investigational, novel, orally administered guanosine nucleotide analog polymerase inhibitor for the treatment of COVID-19. The company is developing bemnifosbuvir and ruzasvir, an investigational nonstructural protein 5A (NS5A) inhibitor for the treatment of chronic HCV infection. The firm is also developing AT-752, an oral, purine nucleotide prodrug for the treatment of dengue. AT-527 is designed to inhibit viral replication by interfering with viral RNA polymerase.
Phase III timing: Top-line readout expected for C-BEYOND midyear 2026 and for C-FORWARD by year-end 2026.
Clinical progress: Global Phase III program is fully enrolled in North America (>880 patients in C-BEYOND) and expected to enroll >1,760 patients combined; Phase III trials are randomized, active-controlled and powered 90% with a 5% noninferiority margin.
Regimen profile: Bemnifosbuvir + ruzasvir demonstrated strong Phase II results (98% SVR12 in the protocol treatment population; 95% SVR12 in the efficacy-evaluable/MITT-type analyses) and a differentiated profile: short 8-week duration for noncirrhotics, low drug–drug interaction risk, no food effect and no dose adjustment for hepatic/renal impairment.
New program: AT-587 selected as lead for HEV; IND/CTA-enabling work underway with first-in-human study anticipated midyear 2026 and PoC by year-end 2026; company estimates HEV market opportunity of $750 million–$1 billion in U.S./Europe.
Commercial prep: Company expects a focused U.S. launch with ~75 commercial hires, blister packaging for adherence, and market research indicating high prescriber interest (physicians said they'd likely use the regimen in ~50% of their patients).
Balance sheet & runway: Cash, cash equivalents and marketable securities were $301.8 million at December 31, 2025; management projects the cash runway extends to 2027. The company returned $25 million to shareholders via share repurchases in 2025.
